Loading...
XSHE000963
Market cap8.67bUSD
Dec 24, Last price  
36.05CNY
1D
1.52%
1Q
21.54%
Jan 2017
50.08%
Name

Huadong Medicine Co Ltd

Chart & Performance

D1W1MN
XSHE:000963 chart
P/E
22.27
P/S
1.57
EPS
1.62
Div Yield, %
0.94%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
5.67%
Revenues
40.39b
+7.10%
2,882,475,1603,484,232,5893,942,455,3214,853,413,4206,016,486,1417,824,872,1648,971,836,50911,131,372,42214,579,230,37416,717,986,44618,947,379,09421,727,383,49425,379,667,50227,831,823,14830,663,374,32635,445,698,21633,683,058,75934,563,301,23337,714,587,45840,391,192,251
Net income
2.84b
+13.59%
30,581,43167,313,91883,351,285173,160,209168,609,741378,421,189317,306,761381,484,999469,927,239574,975,854756,669,4191,096,912,4321,446,591,6981,779,506,0612,267,229,1742,813,118,7022,819,861,2032,301,631,3472,499,214,3592,838,860,542
CFO
3.93b
+64.96%
12,506,256203,330,80857,380,441265,790,560344,689,663567,939,912016,123,655642,729,226476,977,321740,854,724658,536,2561,346,962,8071,661,118,6632,039,496,0832,001,698,1703,411,447,7473,169,757,8672,381,852,6683,929,216,706
Dividend
Sep 20, 20240.35 CNY/sh

Profile

Huadong Medicine Co., Ltd produces and sells various pharmaceutical products in China. It offers Chinese patent drugs, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, medical cosmetology, and antibiotic drugs, as well as medical equipment. The company's products include gastrointestinal agents, APIs, and other products. It also engages in the production and management of traditional Chinese and western raw medicines and preparations, and health care products; wholesale of TCM materials, TCM decoction pieces, chemical preparations, etc.; warehousing and storage business; and research, development, production, and sale of aesthetic medicine products. Huadong Medicine Co., Ltd was founded in 1993 and is headquartered in Hangzhou, China.
URL
https://www.eastchinapharm.com/
IPO date
Jan 27, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
40,391,192
7.10%
37,714,587
9.12%
34,563,301
2.61%
Cost of revenue
34,212,940
33,557,266
30,876,436
Unusual Expense (Income)
NOPBT
6,178,252
4,157,321
3,686,865
NOPBT Margin
15.30%
11.02%
10.67%
Operating Taxes
619,589
498,499
488,907
Tax Rate
10.03%
11.99%
13.26%
NOPAT
5,558,663
3,658,822
3,197,958
Net income
2,838,861
13.59%
2,499,214
8.58%
2,301,631
-18.38%
Dividends
(594,215)
(507,445)
(402,456)
Dividend yield
0.82%
0.62%
0.57%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
822,380
1,095,352
1,482,100
Long-term debt
634,150
1,220,678
300,958
Deferred revenue
42,077
126,124
83,522
Other long-term liabilities
320,586
398,674
300,990
Net debt
(5,320,726)
(3,713,908)
(3,519,105)
Cash flow
Cash from operating activities
3,929,217
2,381,853
3,169,758
CAPEX
(1,606,618)
(819,095)
Cash from investing activities
(1,820,068)
Cash from financing activities
(1,418,361)
FCF
5,414,475
2,607,175
3,683,633
Balance
Cash
4,663,378
3,996,302
4,032,425
Long term investments
2,113,878
2,033,636
1,269,738
Excess cash
4,757,696
4,144,208
3,573,998
Stockholders' equity
17,983,032
17,042,173
14,802,865
Invested Capital
18,587,066
17,358,993
14,424,390
ROIC
30.93%
23.02%
22.68%
ROCE
26.26%
19.15%
20.28%
EV
Common stock shares outstanding
1,751,626
1,749,810
1,749,810
Price
41.45
-11.43%
46.80
16.42%
40.20
51.36%
Market cap
72,604,905
-11.34%
81,891,087
16.42%
70,342,344
51.36%
EV
67,818,834
78,775,701
67,185,183
EBITDA
6,996,599
4,862,870
4,278,428
EV/EBITDA
9.69
16.20
15.70
Interest
144,200
125,100
72,498
Interest/NOPBT
2.33%
3.01%
1.97%